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Treatment of inflammatory bowel disease (IBD) is challenging, with a series of available
drugs each helping only a fraction of patients. Patients may face time-consuming drug
trials while the disease is active, thus there is an unmet need for biomarkers and assays to
predict drug effect. It is well known that the intestinal epithelium is an important factor in
disease pathogenesis, exhibiting physical, biochemical and immunologic driven barrier
dysfunctions. One promising test system to study effects of existing or emerging IBD
treatments targeting intestinal epithelial cells (IECs) is intestinal organoids (“mini-guts”).
However, the fact that healthy intestinal epithelium is in a physiologically hypoxic state has
largely been neglected, and studies with intestinal organoids are mainly performed at
oxygen concentration of 20%. We hypothesized that lowering the incubator oxygen level
from 20% to 2% would recapitulate better the in vivo physiological environment of colonic
epithelial cells and enhance the translational value of intestinal organoids as a drug testing
platform. In the present study we examine the effects of the key IBD cytokines and drug
targets TNF/IL17 on human colonic organoids (colonoids) under atmospheric (20%) or
reduced (2%) O2. We show that colonoids derived from both healthy controls and IBD-
patients are viable and responsive to IBD-relevant cytokines at 2% oxygen. Because
chemokine release is one of the important immunoregulatory traits of the epithelium that
may be fine-tuned by IBD-drugs, we also examined chemokine expression and release at
different oxygen concentrations. We show that chemokine responses to TNF/IL17 in
organoids display similarities to inflamed epithelium in IBD-patients. However,
inflammation-associated genes induced by TNF/IL17 were attenuated at low oxygen
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concentration. We detected substantial oxygen-dependent differences in gene expression
in untreated as well as TNF/IL17 treated colonoids in all donors. Further, for some of the
IBD-relevant cytokines differences between colonoids from healthy controls and IBD
patients were more pronounced in 2% O2 than 20% O2. Our results strongly indicate that
an oxygen concentration similar to the in vivo epithelial cell environment is of essence in
experimental pharmacology.
Keywords: inflammatory bowel diseases, epithelium, organoids, oxygen, cytokines, tumor necrosis factor,
interleukin 17
INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD), collectively
termed inflammatory bowel disease (IBD), are prevalent and
chronic conditions with an incompletely understood
pathobiology involving the immune system, intestinal
epithelium and microbiota. The intestinal epithelial cell (IEC)
monolayer separates gut microbiota from lamina propria
immune cells and influences signaling between microbes and
the immune system, shaping the homeostatic environment of the
healthy gut (Kaser et al., 2010). These processes involve e.g.
secretion of mucus, antimicrobial peptides, IgA and an array
of cytokines, responding to microbes through pattern recognition
receptors (PRRs) (Allaire et al., 2018).
Although there is no cure for IBD, drugs modify disease
course. Basic therapeutics are glucocorticoids and 5-
aminosalicylic acid, and insight into disease mechanisms has
led to biological drugs aimed at cytokines such as e.g. anti-TNF
and anti-IL12/23p40, at α4β7 lymphocyte homing mechanisms,
and lately drugs inhibiting JAK-STAT pathways (Chang and
Hudesman, 2020). Other promising drugs are under
development but not yet approved. A central problem is that
no treatment helps all patients, and little predictive information
can be derived from disease traits of the individual patient. For
instance, anti-TNF biologicals are the primary drugs after failure
of basic treatment, but 30% of patients are primary
nonresponders and 40% of those with an initial effect lose
response (Ben-Horin and Chowers, 2011; Yanai and Hanauer,
2011).
Patients may face time-consuming drug trials while the disease
is active, thus there is an unmet need for biomarkers and assays to
predict drug effect. One promising test system is intestinal
organoids, first developed for stem cell research, disease
modelling and regenerative medicine (Sato and Clevers, 2013).
In IBD, organoids may be used as patient-specific in vitro assays
to predict the clinical response to drugs targeting the IEC. This
would be an important tool for personalized medicine, and may
reveal new and more easily applicable biomarkers for prediction
of treatment response.
Colonic epithelial organoids (colonoids) can be derived from
pinch biopsies with a high success rate. The process is labour-
intensive and cannot be done for all IBD patients. However,
cryogenic preservation of biopsies has made it possible to
generate colonoids at a later point of time for patients with
difficult disease (Tsai et al., 2018). A potential problem has been
seen in colonoids looking at IEC characteristics in UC patients
in vitro, where results diverge. Some studies find persisting
abnormalities possibly due to genetic or epigenetic factors
(Dotti et al., 2017), while in others UC characteristics
disappear (Arnauts et al., 2020). The central question thus
becomes how IEC pathobiology and drug responses can be
studied in colonoids retaining UC characteristics.
The low level of oxygen in the colonic mucosa might be one
important factor in this regard, with oxygen concentration
decreasing from approximately 3% at the crypt base to <1% at
the surface (Litvak et al., 2018; Keeley and Mann, 2019). This has
largely been neglected, and studies on colonoids have been
performed using a standard cell culture oxygen concentration
of 20%. Thus, the aim of the present study was to examine the
inflammatory responses in colonoids from patients with UC, as
compared to healthy individuals, and how an oxygen
concentration of 2% retains colon IEC characteristics and
changes responses to two relevant and important IBD related
cytokines, TNF and IL17.
METHODS
Ethics Approval
The study was approved by the Central Norway Regional
Committee for Medical and Health Research Ethics (Reference
numbers 5.2007.910 and 2013/212/REKmidt). Informed written
consent was obtained from all subjects included in the study.
Patient Material
Patients were included in the study after referral to the Department
of Gastroenterology and Hepatology for colonoscopy. Patients
either received or had a prior diagnosis of UC or CD, or were
included as controls after clinical assessment and a normal
colonoscopy. They were categorized as healthy controls, or UC
or CD with inactive disease or ongoing inflammation, based on
clinical, endoscopic and histological evaluation. Colonic pinch
biopsies were collected and preserved in formalin or snap
frozen in liquid nitrogen. Histopathology was evaluated in
hematoxylin and eosin stained sections by an expert pathologist
as previously described (Granlund et al., 2013). Inflamed samples
were taken from maximally inflamed area with intact epithelium.
Un-inflamed samples, and samples from healthy controls, were
taken from the hepatic flexure. A sample was only included in the
final analysis if there was full concordance between endoscopic and
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histopathological assessment of inflammatory status. Colonic
biopsies from 29 subjects (active IBD (n  12), uninflamed IBD
(n  11) and healthy controls (n  6)) underwent laser capture
microdissection of the epithelial monolayer, as described (Ostvik
et al., 2020). Biopsies from uninflamed mucosa at the hepatic
flexure were taken from an additional six patients (HC 3, UC 3)
to create colonoids for functional assays (Supplementary
File SF1).
Human Colonoid 3D Culture and Treatment
Human colonoids were established from epithelial crypts
collected from colonic pinch biopsies using an optimized
protocol from (Mahe et al., 2015) based on (Jung et al., 2011).
Epithelial crypts were isolated from biopsies and resuspended in
basement membrane matrix (#734–1101, Matrigel® Growth
Factor Reduced (GFR) Basement Membrane Matrix, phenol
red-free, Corning®, New York City, NY, United States), and
crypt suspension was added to pre-warmed plates with 50µl
crypt suspension per well in 24-well plates, and 10µl crypt
suspension per well in 96-well plates. Growth medium (500µl
per well in 24-well plates, 100µl in 96-well plates) contained 50%
Wnt-3A conditioned medium (#CRL-2647, RRID:CVCL_0635,
ATCC, Manassas, VA, United States), 30% Advanced DMEM/
F12 (#12634028, Thermo Fischer Scientific, Bremen, Germany),
and 20% R-spondin conditioned medium (HA-R-Spondin1-Fc
293T Cells; # AMS. RSPO1-CELLS, RRID:CVCL_RU08, AMS
Biotechnology, Abington, United Kingdom) with 10% BSA,
containing factors critical for stem cell growth (Jung et al.,
2011), including Recombinant Human Noggin ((0.1μgml−1,#
(#120–10c, PeproTech, Rocky Hill, NJ, United States),
Nicotinamide (1221.2μgml−1, #N3376–100G, MerckMillipore,
Burlington, MA, United States), N-Acetyl-L-cysteine
(163.2μgml−1, #A9165–25G, Sigma-Aldrich, MO,
United States), Inhibitor of TGFβ type 1 activating receptor-
like kinase (ALK5) A-83–01 (0.211μgml−1, #SML0788, Sigma-
Aldrich), MAPK inhibitor SB202190 (3.31μgml−1, #S7067,
Sigma-Aldrich), Human EGF (0.05μgml−1, #AF-100–15,
PeproTech) and Gastrin (0.02μgml−1, G9145-.1MG, Sigma-
Aldrich). For establishment of colonoids, the growth medium
was supplemented with GSK inhibitor CHIRR99021 (1.16μgml−1,
#72052, STEMCELL Technologies, Vancouver, Canada) and
ROCK inhibitor Thiazovivin (0.78μgml−1, #72252, STEMCELL
Technologies), while after passaging (every 7–10 days) the
selective ROCK-inhibitor Y-27632 (3.203μgml−1, #1254, Bio-
Techne, Minneapolis, MN, United States) was added during
the first three days of culture. For passaging, colonoids were
dissociated into single cell suspension by incubation with TrypLE
Express (#12605028, Gibco™, Thermo Fischer Scientific) at 37°C
for 10–15min, followed by gentle pipetting using a syringe with
an 18G fill needle and centrifugation for 5min at 500 x g. The cells
were then resuspended in Matrigel. For experiments, colonoids
were cultured in 20% O2 and 5% CO2 at 37°C for 10 days, with
medium change every 2–3 days, followed by four days of
differentiation before experiments. In differentiation medium,
the amount of Wnt-3A conditioned medium was reduced to 5%
of the volume and Nicotinamide and SB202190 removed, while
the pan-NOTCH inhibitor DAPT (4.3μgml−1, #2634, Bio-
Techne) was added. During proinflammatory treatment
experiments, A-83–01 was removed. For assays in low oxygen,
half of the culture plates were moved from 20% O2/5% CO2 to a
separate incubator (New Brunswick Galaxy 170R CO2,
Eppendorf) in which an additional N2 gas input was used to
calibrate the oxygen level to 2% O2. The colonoids were kept at
2% O2/5% CO2 at 37°C for 40h before sample collection.
Functional Assays in Human Colonoids
Fully formed, undifferentiated colonoids were passaged and
seeded at 500,000 cells. ml−1. Matrigel per well, determined by
cell counting on an automated cell counter (Countess II
Automated cell counter, Thermo Fischer Scientific). After
differentiation as described above, proinflammatory treatment
experiments were carried out using TNF (100ngml−1, #300-01A,
PeproTech) and IL17 (100ngml−1, #200-17, PeproTech) diluted
in growth medium, alone or in combination for 24h, with
untreated colonoids receiving growth medium as controls, at
20% or 2% O2. For experiments at 2% O2, colonoids were pre-
equilibrated for 16h before treatment and kept at 2% O2 until the
assay was completed. At 16h, ligand preparations or growth
medium without ligand (untreated) was added in 1/10 of the
total volume of growthmedium, to avoid complete reoxygenation
in the 2% O2 conditions. Conditioned media were collected,
centrifuged to remove cell debris, and stored at -80°C.
Colonoids were collected using Cell Recovery Solution (CRS)
(#734-0107, Corning, NY, United States) which depolymerizes
Matrigel, and washed with PBS/0.1% BSA and centrifuged (500 x
g) three times. Colonoid pellets were snap-frozen in liquid
nitrogen and stored at -80°C or prepared for
immunohistochemistry or protein measurement in cell lysate,
as described below.
Confocal Imaging of Colonoids
To assess morphology and presence of dead cells in the colonoid
culture, high resolution imaging using a Leica TCS SP8 confocal
microscope, equipped with an HC PL APO CS2 20x/0.75 NA
water immersion objective (Leica Microsystems, Mannheim,
Germany) was performed. Cells were stained with NucBlue®
Live reagent (Hoechst 33342) for all cell nuclei and propidium
iodide for dead cell nuclei (ReadyProbes Viability Imaging kit,
Blue/Red, #R37610, Invitrogen) added directly to the cell culture
10min prior to imaging. The samples were excited by the 405nm,
and 561nm laser lines from a White Light Laser (WLL) and
fluorescence emission detected sequentially by hybrid detectors
(HyD) in the spectral ranges 420–500nm and 580–670nm,
respectively. Images were captured using LAS X (RRID:
SCR_013673, Leica) software, at 12-bit depth, with a pinhole
corresponding to 1 airy unit (at 580nm), and were post processed
by linear histogram stretch (normalization) and maximum
Z-projections in Fiji (RRID:SCR_002285) (Schindelin et al.,
2012). All confocal images are maximum Z-projections based
on 40–50 optical sections.
Flow Cytometry
Differentiated organoids were either maintained in 20% or
transferred to 2% O2 for the last 40h before being harvested
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and dissociated into single cell suspension by incubation with TrypLE
Express (#12605028, Gibco™, Thermo Fischer Scientific) for 20min
and careful pipetting with a 1000µl tip. Cells were washed with PBS
with 2%FCS and centrifuged at 240 x g, and then incubated for 15min
at 4°C with Fc-blocking reagent and antibodies against CD326 (1:200)
(#324233, APC-Fire, RRID:AB_2629702), CD24 (1:200) (#311123,
BV605, RRID:AB_2562287), CD44 (1:200) (#103017, AF647, RRID:
AB_493680), CD117 (1:200) (#313211, PE-CY7, RRID:AB_893228)
all from BioLegend (San Diego, CA, United Staes). Further,
rhodamine-labelled UEA1 lectin (1:500) (#RL-1062 1mgml−1,
rhodamine, RRID:AB_2336769) from Vector laboratories
(Burlingame, CA, United States) was used for identifying secretory
cells. Antibodies and UEA-1 were diluted in PBS with 2% FCS.
Samples were washed and stained with DAPI (1:1000 in PBS with 2%
FCS) for live-dead exclusion, filtered through a 100µM mesh and
immediately analyzed on a BD LSRII flow cytometer. BD CompBead
anti-mouse Ig/anti-rat IG (#552843, RRID:AB_10051478, BD
Biosciences, Franklin Lakes, NJ, United States), were used for
antibody compensation controls. Post-acquisition analysis was
carried out with FlowJo (RRID:SCR_008520, version 10).
Immunohistochemistry of Colonoids
Colonoid-pellets were resuspended in 50µl Richard-Allan
Scientific™ HistoGel™ Specimen Processing Gel (# HG-4000-
012, Thermo Fisher Scientific) before being fixed in formalin for
24–48h and embedded in paraffin. Colonic biopsies were fixed in
10% buffered-formalin for 3–6days before embedding in paraffin.
Formalin-fixed paraffin-embedded (FFPE) sections were
processed through standard de-paraffinization and quenching
of endogenous peroxidase before IHC. Antigen retrieval was
achieved by 15min boiling in citrate buffer (pH 6.0) using a
commercial microwave oven. All sections were incubated
overnight at 4°C with primary mouse monoclonal anti-human
antibody against HIF1α (#MA1-16504, RRID:AB_568567,
Invitrogen, Thermo Fisher Scientific, MA, United States) or
Ki67 (#M7240, RRID:AB_2142367, Dako Agilent, Santa Clara,
CA, United States) diluted 1:20 (a-HIF1α) or 1:100 (a-Ki67) in
PBS with 0.25% Triton-X and 0.25% BSA freshly used from
frozen aliquotes. For a-HIF1α an additional 15min incubation
with EnVision FLEX +Mouse (LINKER) (#K8021, Dako Agilent)
was used. Immunoreactions were visualized using the rabbit/
mouse EnVision-HRP/DAB + kit (#K5007, Dako Agilent) and
counterstaining with hematoxylin. Negative controls were
omission of primary antibody and similar concentration of
matching-isotype non-immunized IgG. Images were captured
by Nikon Eclipse Ci microscope, DS-Fi1 camera and NIS-
Elements BR imaging software (Nikon Corporation, Tokyo,
Japan). Further processing was done using Photoshop (Adobe
Photoshop CC, 20.0.6 Release) and Fiji (RRID:
SCR_002285)(Schindelin et al., 2012). Quantification of the
Ki67 and HIF1α IHC staining was done using Fiji images with
10x and 40x magnification, respectively. In each group, a total
number of 500-5000 (Ki67) or 250-800 (HIF1α) nuclei from
several images were counted in four to five independent
experiments, and the percentage of positive nuclei averaged
within each experiment.
Detection of Apoptosis in Colonoids
To assess apoptosis, the Caspase-Glo 3/7 Assay (#G8090,
Promega, Madison, WI, United States) was used according to
manufacturer’s instructions. The assay was performed three
times, with three technical replicates, on colonoids grown in
96-well plates untreated or treated with ligands at 20% or 2% O2.
Luminescence was measured on a Victor3 plate reader
(PerkinElmer, Waltham, MA, United States).
Blood Gas Analyzes of ConditionedMedium
From Colonoids
An ABL90FLEX plus blood gas analyzer (Radiometer Medical,
Brønshøj, Denmark) was used according to manufacturer’s
instructions to measure and compare pH and concentrations
of glucose and lactate in conditioned medium from colonoids
grown at 20% or 2% O2 for the last 40h.
RNA Extraction and Gene Expression
Analysis
RNeasy Mini kit (#74106, Qiagen, Hilden, Germany)
(colonoids) and RNeasy Micro Plus (#74034, Qiagen)
(microdissected epithelial monolayer) were used for RNA
extraction, according to the manufacturer’s protocol. For
RNA-Seq of colonoids, the total RNA concentration was
measured using a Qubit RNA HS Assay Kit on a Qubit 2.0
Fluorometer (Thermo Fisher Scientific, Waltham, MA,
United States). Integrity was assessed using an Agilent RNA
6000 Nano Kit on a 2100 Bioanalyzer instrument (Agilent
Technologies, Santa Clara, CA, United States). RNA
sequencing libraries were generated using SENSE FFPE total
RNA-Seq library prep kit (with RiboCop rRNA depletion)
according to manufacturer’s instructions (Lexogen GmbH,
Vienna, Austria). Libraries were normalized and pooled to
2.4nM and subject to clustering by a cBot Cluster Generation
System on HiSeq4000 flowcells (Illumina Inc., San Diego, CA,
United States), according to manufacturer’s instructions. The
sequencing (75 cycles single end reads) was performed on an
Illumina HiSeq4000 instrument, in accordance with the
manufacturer’s instructions (Illumina). FASTQ files were
created with bcl2fastq 2.18 (RRID:SCR_015058, Illumina).
Transcript expression values were generated by quasi
alignment using Salmon (Patro et al., 2017) and the Ensembl
(GRCh38) human transcriptome. Aggregation of transcript to
gene expression was performed using tximport (RRID:
SCR_016752) (Soneson et al., 2015). Gene expression values
with CPM (counts per million) below one in more than three
samples were filtered out before differential expression analysis.
Laser capture microdissection (LCM) of epithelial cells from
colonic biopsies was performed as previously described (Ostvik
et al., 2020). Approximately 10,000 epithelial cells (1mm2) were
acquired by LCM and cells were immediately lysed in RNeasy
Micro Plus lysis buffer (300µl) and kept at -80°C. Illumina TruSeq
RNA access library kit (Illumina) was used to prepare libraries for
RNA-Seq, according to the manufacturer’s protocol.
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Quantitative Real-Time PCR
Total RNA isolated from colonoid pellets was stored in cryotubes
in liquid nitrogen. The High-Capacity RNA-to-cDNA kit
(Applied biosystems) was used for reverse transcription, and
qPCR performed using PerfeCTa assay with PerfeCTa qPCR
FastMix (Quantabio, Beverly, MA, United States) and Taqman
probes (Applied biosystems), EPAS1: probe ID Hs01026149,
CA9: probe ID Hs00154208, VEGFA: probe ID Hs00900054)
with housekeeping genes (TBP: probe ID Hs0042760, ACTB:
probe ID Hs01060665). StepOnePlus Real-Time PCR system
with StepOne software version X (RRID:SCR_014281, Applied
Biosystems) was used. Fold changes were calculated using the
delta-delta CT method. RNA-seq data is available at Gene
Expression Omnibus (GEO) under the accession number
GSE172404.
Bioinformatics and Gene Set Enrichment
Analysis
Initial interpretation of data was done using the unsupervised
dimensionality-reduction method of Principal Component
Analysis (PCA). Differential gene expression of microdissected
colonic epithelium were identified using R package limma (voom,
RRID:SCR_010943) with an adjusted p value < 0.05 between
paired experimental conditions. Differential gene expression of
colonoids were identified using R package DESeq2 (RRID:
SCR_015687) (Love et al., 2014) with an adjusted p value
<0.05 between paired and unpaired experimental conditions.
Enrichment analyses were done in MetaCore™ version 6.34
build 69,200 (Clarivate Analytics, Philadelphia, PA).
Multiplex Chemokine Profiling and ELISA
The Bio-Plex Pro Human Chemokine Panel, 40-plex
(#171ak99mr2, Bio-Rad laboratories, Hercules, CA,
United States) was used according to the manufacturer’s
instructions to detect cytokines in conditioned medium from
colonoids stimulated at 20% or 2% O2. Of the 40 cytokines, 30
were chemokines and 10 belonged to other cytokine groups
including interferons, IL-1 family and growth factors.
Cytokines with release <100pg ml−1 were excluded from
further assessment. ELISA kits for human CXCL1 (DY275-05),
CXCL2 (DY276-05), CXCL5 (DY254-05), CXCL8 (DY208),
CXCL10 (DY266-05), CXCL11 (DY672) and CCL20 (DY360),
all from R&D Systems (Abington, United Kingdom), were used
according to manufacturer’s protocols.
Materials
Supplementary file SF2 lists materials described in the
text above.
Statistical Analysis
Except for the Bioinformatics and Gene set enrichment analyses
described above, statistical analyses were performed in GraphPad
Prism 8.0 (RRID:SCR_002798, GraphPad Software Inc., San
Diego, CA, United States). For normally distributed numerical
values and log2 transformed data, differences between groups
were evaluated by one sample t-test, paired t-tests or ANOVA
with multiple comparison tests with p-value correction, as
indicated in the figure legends. Briefly, Tukey’s multiple
comparison test was used when comparing every treatment
with every other treatment and Holm-Šídák test when selected
groups were compared. For data not following Gaussian
distribution according to Shapiro-Wilk test, Kruskal Wallis
test followed by Dunn’s multiple comparisons test were used
to compare three or more groups, or Wilcoxon matched-pairs
signed rank tests or Mann-Whitney U test were used to compare
two groups. When ANOVA was used, post-hoc tests were
conducted only if F was signi?cant and there was no variance
in homogeneity. p < 0.05 was considered significant for all
analyses. Data used for plotting and statistics are shown in
Supplementary Data Sheet 2.
RESULTS
Human Colonoids Were Viable and
Responsive to IBD-Relevant Cytokines at
2% Oxygen
Intestinal epithelial organoids are usually grown in 20% O2,
which is much higher than available oxygen for intestinal
epithelial cells in vivo. We hypothesized that lowering the
incubator oxygen level from 20% to 2% would mimic in vivo
physioxia in the colonoids and induce alterations relevant for IEC
functions. Colonoids from 6 donors (Supplementary File SF1)
were grown and differentiated into 3D structures with budding at
20% O2 (Figures 1A,B). Further, the colonoids were either
transferred to 2% O2 or kept at 20% O2 for 40h prior to
collection of media and cells for downstream assays
(Figure 1A). Live imaging of colonoids showed that these
were morphologically similar in 20% O2 and 2% O2 (Figure 1B).
To see whether reduced oxygenation induced changes in cell
composition, colonoids grown at 20% or 2% O2 were dispersed
into single cells and stained with the markers CD326 (expressed
by colonic epithelial cells), CD24 (expressed by e.g., stem cells),
CD44 (expressed by e.g., proliferating cells), CD117 and UEA1
(expressed by e.g., secretory cells) (Figure 1C). We found no
significant changes in expression of these markers with different
oxygen concentrations. Moreover, IHC staining for Ki67 in
sections of paraffin embedded colonoids did not show
different proliferation rates between 20% and 2%O2 (Figure 1D).
Since hypoxia inducible transcription factors (HIFs) are
stabilized and translocated to the cell nucleus in response to
reduced oxygenation (Van Welden et al., 2017; Watts and
Walmsley, 2019) we examined intracellular HIF1α expression
in colonoids by IHC staining. HIF1α was detected in both
cytoplasm and nuclei. Quantitative measurements showed
significantly higher percentages of HIF1α positive nuclei in
colonoids exposed to 2% O2 compared to 20% O2 (Figure 1E,
Supplementary Data Sheet 2), indicating a nuclear translocation
of the protein. Consequently, RT-qPCR showed that the
expression levels of the classical HIF target genes carbonic
anhydrase 9 (CA9), phosphoglycerate kinase 1 (PGK1) and
VEGFA increased significantly in 2% compared to 20% O2
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FIGURE 1 | Effects of oxygen concentration on growth, cell-death, gene expression and metabolism in human colonoids (A). Experimental design. Differentiated
colonoids from six donors were either grown continuously at 20% O2 or calibrated at 2% O2 for 16h before treated with TNF (100ngml
−1), IL17 (100ngml−1) or a
combination (TNF/IL17) for 24h (B) Detection of morphology and cell death by live imaging of untreated colonoids. Left image shows a 3D depth encoded image of one
colonoid at 20%O2, according to the color scale from red (superficial) to blue (deep) on the right side of the image. Center and right image panels show colonoids in
20% or 2%O2 respectively, where NucBlue
®
Live reagent (Hoechst 33342) stains all cell nuclei (blue) and propidium iodide stains dead cell nuclei (red). Scale bars 100µm
(C) Expression of epithelial cell markers as measured by flow cytometry in untreated colonoids from three donors, in 20%O2 or 2%O2 as depicted in panel (A) (n  3 + 3
(Continued )
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(Figure 1F). Blood gas analyses of conditioned medium from the
colonoids showed that reduced oxygen concentration led to
increased glucose consumption followed by lactate production,
resulting in a decreased medium pH (Figure 1G).
Next, we examined how IBD-drug targets such as TNF, IL17
or a combination of both (TNF/IL17) altered colonoid
morphology at different O2 concentrations. Live imaging with
staining of dead cells and caspase 3/7 assay, showed a similar
trend in both 20% and 2% O2, where TNF affected cell survival
compared to untreated colonoids. Adding IL17 together with
TNF enhanced cell death, while IL17 alone had no effect on
morphology (Figure 1H) or caspase 3/7 activity (Figure 1I) when
compared to untreated colonoids.
In sum, we induced a HIF response in colonoids when
reducing oxygen level from 20% to 2% O2 for 40h, with
upregulation of classical HIF target genes and a clear shift in
metabolism as expected (Lanis et al., 2017). Moreover, the
colonoids were responsive to TNF and IL17 in both 20% and
2% O2. The proinflammatory cytokine TNF induced, particularly
in the combination with IL17, high level of cell death which was
maintained across different O2 concentrations. Thus, the
colonoids were fully viable at the 2% O2 level and exhibited
unaltered morphology between 20% and 2% O2 when treated
with IBD drug targets. This shows that colonoid assays can be
performed in 2% O2 which may recapitulate better the in vivo
physiological environment of colonic epithelial cells.
Inflammation-Associated Genes Induced by
TNF and TNF/IL17 Were Attenuated at 2%
Oxygen
In the complex cytokine landscape of both the healthy and the
diseased gastrointestinal mucosa, TNF is an important IBD-
associated proinflammatory cytokine (Murch et al., 1993; Breese
et al., 1994; Nanki et al., 2020), and IL17 modulates the effect of
other cytokines (Amatya et al., 2017). We therefore analysed the
effects of TNF and TNF/IL17 on gene expression in colonoids
grown under standard cell culture oxygen concentration of 20%
and lower, more physiological level of 2%. There was no significant
change in the expression of TNF-receptors TNFRSF1A/1B and the
IL17 receptor IL17RA at 2% and 20% O2, or in untreated and
cytokine treated colonoids (Supplementary Figure S1). Compared
to untreated colonoids, cytokines regulated fewer genes in 2% O2
than in 20% O2 (Table 1, GEO, GSE172404). Enrichment analysis
of gene expression in colonoids treated with TNF compared to
untreated colonoids in 2% and 20% O2 showed a strong
overrepresentation of genes in networks related to inflammation
(Figure 2A, Supplementary Data Sheet 2) such as "Immune
response_Antigen presentation”, “Inflammation_Neutrophil
activation,” “Inflammation_IL-10 anti-inflammatory response,”
“Inflammation_Innate inflammatory response,” and “Chemotaxis”.
There was substantial overlap between top ten networks in the
enrichment analysis for TNF or TNF/IL17 compared to the
untreated colonoids. Overall, 20% O2 gave stronger associations to
the network categories involved in inflammation compared to 2%O2,
with more genes mapping to the networks, and this effect was most
prominent for the networks “Chemotaxis” and
“Inflammation_Innate inflammatory response.”
Colonoid Chemokine Responses to TNF
and TNF/IL17 Showed Similarities to
Inflamed Epithelium
In the intestinal mucosa, chemotaxis of immune cells is
regulated by chemokines released from both immune cells
and IECs (Skovdahl et al., 2015; Kvedaraite et al., 2016;
Trivedi and Adams, 2018). Because chemokine release is one
of the important immunoregulatory traits of the epithelium
that may be fine-tuned by IBD-drugs (Trivedi and Adams,
2018) we first used RNA-Seq to identify the expression of
chemokines in microdissected epithelium from IBD patients
with active inflammation (n  12), compared to non-inflamed
mucosa from IBD patients in remission (n  11) and healthy
controls (n  6). We found differential expression of several
important chemokines and chemokine receptor (Figure 2B).
To further investigate the regulation of epithelial chemokine
expression, we compared chemokine and chemokine receptor
gene expression in microdissected epithelium (Figure 2B) to
the expression in colonoids (Figure 2C) at both 20% and 2%
O2. The treatment with TNF or TNF/IL17 in colonoids led to
altered/increased expression of the chemokines CCL20, CCL28,
CX3CL1, CXCL1, CXCL2, CXCL3, CXCL8, CXCL10, CXCL11
and CXCL16 and the chemokine receptor CXCR4, which
corroborated the chemokine expression in the
microdissected epithelium from inflamed biopsies
(Figure 2C, GEO, GSE172404). These data suggest that the
colonoid model could be used to study chemokines that are
overexpressed in IEC during active IBD.
FIGURE 1 | for each marker). Relative change between oxygen concentrations normalized to 20% O2 (red line at y  1) displayed, with mean and individual normalized
values (D) and (E) Immunostaining of differentiated colonoids grown at 20% or 2% O2, representative selection from five assays. Scale bars 50µm. (D) Ki67 positive
nuclei stained brown, counterstaining with hematoxylin. The graph shows percentage of Ki67 positive nuclei in four independent experiments indicated by dots. Bars
show mean with SD (E) HIF1α translocated to nuclei shown in brown counterstaining with hematoxylin. The graph shows percentage of HIF1α positive nuclei in five
independent experiments indicated by dots. Bars showmean with SD. *p < 0.05 (Mann-Whitney U test) (F) Expression of the HIF target genesCA9, PGK1 and VEGFA in
untreated colonoids (n  6) at 20% or 2% O2 (n  6) by RT-qPCR. Mean fold change relative to housekeeping gene (ACTB) with SD and individual values is given. Paired
t-tests were used to detect difference between 20 and 2% O2 (*p < 0.05) (G) pH, Lactate (mmol.L−1) and glucose (mmol.L−1) in conditioned medium from untreated
colonoids (n  6) grown at 20% or 2% O2 for 40h. Median with CI and individual values shown. Differences determined using Wilcoxon matched-pairs signed rank test
(*p < 0.05) (H) Imaging of colonoids at 20% or 2% O2, after treatment for 24h with TNF or IL17 alone or in combination (TNF/IL17). Staining performed as in (B). Scale
bars 100µm (I) caspase 3/7 activity in untreated, TNF, TNF/IL17 or IL17 treated colonoids grown at 20% or 2%O2. Mean luminescence normalized to untreated at 20%
O2 and individual values shown from three independent assays. Significant cytokine induced apoptosis determined by Kruskal Wallis test followed by Dunn’s multiple
comparison test (*p < 0.05). No difference found between oxygen concentrations (paired t-test).
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The expression of chemokines CCL20, CCL28, CXCL1,
CXCL2, CXCL3 CXCL5 and CXCL6 were more regulated by
the TNF/IL17 treatment when compared to TNF treatment
alone whereas the expression of CX3CL1, CXCL10, CXCL11,
CXCL16 and CCL2 was driven more by TNF treatment in
comparison to TNF/IL17 treatment. Moreover, similar levels
of CXCL8 and CCL22 was observed across both TNF and
TNF/IL17 treatment. Importantly, the RNA Seq analysis in
colonoids also indicated that oxygen levels affected chemokine
expression (Figure 2C, GEO, GSE172404). For example, the TNF
or TNF/IL17 induced expression of CCL28, CCL2, CXCL5,
CXCL10, CXCL11 and CXCL6 were, or trended towards being,
downregulated at reduced oxygen concentration, while CCL22,
CXCL8 and receptor CXCR4 expression were upregulated at 2%
O2 compared to standard cell culture concentration.
We further examined alterations in chemokine protein release
upon stimulation with IBD drug targets across different O2
concentrations. Conditioned medium from untreated colonoids
and TNF or TNF/IL17 treated colonoids at 2% and 20% O2 were
screened by a multiplex assay measuring 40 cytokines. We found
that TNF or TNF/IL17 treatment induced release of 18 different
chemokines into the conditioned media. (Figure 3A,
Supplementary Data Sheet 2). These included nine of the
chemokines upregulated in epithelium from IBD patients
(Figure 2B, CCL20, CCL24, CX3CL1, CXCL1, CXCL10,
CXCL11, CXCL16, CXCL2, CXCL8). The multiplex screening
further suggested a reduced release of 11 chemokines in 2% O2
compared to 20% O2 (Figure 3A panels 1 and 3). Two chemokines
had increased release in 2% O2 (panel 2) and five chemokines had
similar release in both oxygen concentrations (panel 4).
To confirm multiplex results, we performed ELISA on
conditioned medium from six donors (3 healthy controls +
3UC) for CXCL1, CXCL2, CXCL5, CXCL8, CXCL10, CXCL11
and CCL20 (Figure 3B, Supplementary Data Sheet 2), which
verified epithelial release and an effect of TNF and/or TNF/IL17
treatment. Further, the release of all these chemokines except for
CXCL8 was attenuated in 2% compared to 20% O2 and were in
line with observations made with the multiplex data.
Donor Differences in Cytokine Responses
at 20% and 2% O2
Since patient-derived organoids retain donor characteristics they
may be used to study donor-differences in response to extracellular
stimuli and drug-target-responses. Unsupervised analysis (PCA) of
global gene expression across all conditions in colonoids from the
six donors showed indeed that the dominating sources of variation
in the two first principle components (19.1% explained variance)
separated donors and oxygen levels into distinct clusters
(Figure 4A). Inspecting the first four components in the PCA
analyses of colonoids from the six donors individually, clear
separations (22.1%–30.6% explained variance) were seen
between untreated vs. TNF or TNF/IL17 treated colonoids. We
also observed clear separation between TNF and TNF/IL17 treated
colonoids as well as between oxygen levels in varying sets of the
four dimensions PC1 to PC4 (Figure 4B). Thus, the drug-targets
TNF/IL17 induced strong responses in all donors that also could be
separated by oxygen level.
In the PCA of global gene expression across all conditions in
colonoids from the three HC donors and three UC donors, we also
observed a moderate clustering based on disease status. Despite the
individual donor variances, the second and third principle
components captured the difference between HC and UC
colonoids (untreated, TNF, TNF/IL17 in 2% and 20% O2)
(Figure 5A). Exploring the gene lists (GEO, GSE172404) we
found that e.g., the highly relevant IBD-cytokines IL23, IL1A and
IL1B were higher expressed in colonoids from UC compared to
healthy control colonoids upon TNF and TNF/IL17 treatment,
particularly in 2% O2 (Figure 5B). Thus, we found differential
expression of genes relevant to mucosal inflammation between UC
and healthy control donors upon treatment with proinflammatory
triggers in 2% O2, which would not be detected in 20% O2.
DISCUSSION
Although it is well known that physical, biochemical and
immunologic driven barrier dysfunctions of epithelial cells
have critical roles in the pathogenesis and perpetuation of IBD
(Kaser et al., 2010; Parikh et al., 2019), there is limited
information about how drugs commonly used in IBD act on
the epithelium in disease. Moreover, the response to a given drug
can not be predicted on the individual level in daily clinical
practice. To achieve individualized, targeted therapies in IBD, we
need a better understanding of this clinical heterogeneity
observed among patients. We have previously confirmed that
organoids developed from human colonic tissue (colonoids)
contain stem cells and all differentiated cell lineages present in
the colonic epithelium, and develop a 3D structure with budding
crypts and surface areas encircling the lumen (Ostvik et al., 2020).
Thus, from our results and those from others (Dotti et al., 2017;
Arnauts et al., 2020; Sayoc-Becerra et al., 2020) colonoids emerge
as a putative tool to study effects of existing or emerging IBD
treatments targeting epithelial cells even in a specific patient.
TABLE 1 | Cytokine regulated genes in colonoids.
Contrasts 2% O2 20% O2
Upregulated Downregulated Upregulated Downregulated
TNF vs untreated 391 304 467 380
TNF/IL17 vs untreated 574 782 757 925
Number of significantly regulated protein coding genes (adjusted p-value < 0.05) in TNF and TNF/IL17 treated colonoids compared to untreated controls (see GEO, GSE172404 for
complete list of gene expression data).
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FIGURE 2 | Effects of TNF and IL17 on inflammation-related genes in colonoids at 20% or 2% O2 (A) Enrichment analysis of RNA-Seq data from colonoids after
treatment with TNF or TNF/IL17 compared to untreated control at 20% or 2% O2. Gene ontology (GO) networks strongly associated with the differentially regulated
genes (adjusted p values are all <0.05) are shown, with bars illustrating the statistical significance of the association (−Log10 false discovery rate (FDR)). The numbers of
genes associated with the GO networks at 20% or 2%O2 are listed on the right. Enrichment analyses were performed using MetaCore™ version 6.34 build 69200
(Supplementary Data Sheet 2) (B) Upregulated chemokine and chemokine receptor genes in microdissected colonic epithelium from active IBD (n  12) compared to
uninflamed epithelium (healthy controls and IBD in remission, n  17) shown as Log2 fold change (heatmap with upregulated genes) and adjusted p values (gray scale) (C)
(Continued )
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To best utilize an in vitromodel experimental conditions should
closely mimic the in vivo environment. This concept is used also in
other fields of biology e.g. during culture of haematopoietic stem
cells (Jez et al., 2015) where in particular oxygen concentration has
been found to be important. We thus chose to study the effect of
oxygen at a low level physiological for the colonic mucosa, and
compare with the commonly used atmospheric oxygen
concentration which leads to a cellular oxygen concentration
never seen in vivo (Keeley and Mann, 2019; Okkelman et al.,
2020). Our results from experiments at 2% O2 reflect the findings
by others, where during low oxygen levels, the HIF1 complex
translocates to the nucleus initiating a transcriptional program
(Van Welden et al., 2017; Watts and Walmsley, 2019) aimed both
at adjusting the cell metabolism to consume less oxygen, and to
maintain cell integrity. Essential for the colonoid model, we found
no differences in cell composition, morphology or cellular
apoptosis suggesting that colonoids cultured under a
physiological, low oxygen concentration were fully viable.
Relevance to IBD is suggested by studies in experimental colitis
models (Sun et al., 2019; Colgan et al., 2020; Yin et al., 2020), and
cell lines (Muenchau et al., 2019; Vissenaekens et al., 2019), which
indicate a protective stabilization of HIF1α, attenuating mucosal
inflammation and promoting barrier formation. Moreover,
reagents that activate HIF via inhibition of the prolyl
hydroxylase enzymes, are suggested to induce hypoxia-mediated
resolution in patients with intestinal mucosal inflammatory disease
(Glover and Colgan, 2011; Brown et al., 2020).
Further experiments were done to compare immunoregulatory
responses to the highly IBD-relevant proinflammatory cytokines
TNF/IL17 at 20% and 2% O2. Our main finding was that 20% O2
gave stronger associations to inflammation-associated gene
network compared to 2% O2. We continued to focus on
chemokines since our previous studies (Ostvik et al., 2013;
Skovdahl et al., 2015; Ostvik et al., 2020) and analysis of
chemokine mRNA level in inflamed microdissected epithelium
indicate that intestinal epithelial cells express and release several
chemokines during active IBD that can affect the recruitment of
both inflammatory and regulatory immune cells to the intestinal
mucosa. A better understanding of how these chemokines are
regulated is important for targeted therapy (Trivedi and Adams,
2018). Our data from human colonoids demonstrated that TNF/
IL17 increased both expression and release of chemokines known
to attract neutrophil granulocytes and monocytes (CXCL1,
CXCL2, CXCL5, CXCL8), compared to TNF alone. A similar
response in vivo may thus reinforce an acute response through
neutrophil attraction. In support of this, previous studies on IL17
receptor deficient mice show reduced neutrophil recruitment and
increased susceptibility to infections (Ye et al., 2001). TNF/IL17
treatment in colonoids induced mRNA expression and release of
CCL20, whereas expression and release of CXCL10 and CXCL11
were reduced, compared to TNF alone. CCL20 is reported to attract
effector Th17 cells, T-regulatory cells (Treg) and plasma cells
(Williams, 2006; Wang et al., 2009). CXCL10 and CXCL11 are
thought to have opposite roles, where CXCL10 preferentially
attract inflammatory Th1 cells and NK cells, whereas CXCL11
attracts Treg1 cells (Karin and Razon, 2018). Thus, a combined
effect of TNF/IL17 in intestinal epithelial cells in vivo and the
subsequent release of CXCL10, CXCL11 and CCL20may influence
the balance between the effector and regulatory T-cells, with an
influx of Th17 cells, as discussed by (Lee et al., 2008).
While TNF/IL17 induced inflammatory responses at both 20%
and 2% O2, the effect on CXCL1, CXCL2, CXCL5, CCL20,
CXCL10 and CXCL11 mRNA expression and protein release
was less prominent at 2% O2. The overall assessment of our
data is a reduction in TNF and TNF/IL17 induced responses in
2% O2, corresponding to the anti-inflammatory traits of hypoxia
seen in other experimental systems (Sun et al., 2019; Colgan et al.,
2020; Yin et al., 2020). Thus, our results suggest that if correctly
tuned, a HIF-response in the epitheliummay partly normalize the
chemokine levels seen in the inflamed mucosa. More important,
our results indicate that functional studies performed in patient-
derived colonoids at unphysiological oxygen level might
exaggerate cellular responses to drug-targets and thereby mask
more subtle differences. Although we found a considerable
donor-dependent variance in the colonoid assays, we were able
to detect substantial oxygen-dependent differences in gene
expression in untreated as well as TNF/IL17 treated colonoids
in all donors. Interestingly, for some of the IBD-relevant
cytokines donor differences based on disease status were more
pronounced in 2% O2 than 20% O2.
In the present study we show that human colonoids adapted
well to short time low (2%) oxygen. The cultures were maintained
at rather low colonoid density to minimize heterogeneity in
oxygen level and nutrients in the wells. A limitation of the
study is that we did not measure real time O2 concentration
and dynamics in our cultures at 20% and 2% O2. Generally, 3D
organoid cultures can have variable oxygen concentration due to
the media height, oxygen diffusion within theMatrigel, individual
organoid size, oxygen consumption rates and metabolic demands
for different cell types (Okkelman et al., 2017; Okkelman et al.,
2020). By live cell imaging of mouse small intestinal organoids
(enterocytes) grown at 20% O2, Okkelman et al. (2017) showed
that O2 diffusion provided rather uniform oxygenation in the
Matrigel matrix. However, their method revealed pronounced
heterogeneity in oxygenation (2.8–9.7% O2) both within and
between individual organoids, that might be explained by
differences in aerobic metabolism of various cell types. Studies
in 2D cell line cultures indicated an optimal physioxic range low
FIGURE 2 | Chemokine gene expression in colonoids from six donors, treated with TNF or TNF/IL17 for 24h in 2 and 20% O2. Examples of significantly (p < 0.05)
regulated chemokines and receptors are shown, determined using LIMMA linear models with least squares regression and empirical Bayes moderated t-statistics with
Benjamini Hochberg false discovery rate correction for multiple comparisons (B,C). * without lines show significant alterations due to drug-target treatments when
compared to untreated controls whereas * above lines show significant comparisons made between TNF and TNF/IL17. # above lines show significant differences
between 2% oxygen and 20% O2 within a specific treatment condition.
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FIGURE 3 | Chemokines released by colonoids at 20 or 2% O2. Conditioned medium from colonoids at 20 or 2% O2, followed by 24h treatment with TNF, IL17 or
TNF/IL17, and untreated colonoids were analyzed for chemokine concentration (A) Mean protein concentration (pg.ml−1) of chemokines in conditioned medium from
colonoids (n  3 independent assays) analyzed by Human Chemokine Panel featuring 40 magnetic bead-based immunoassays. The 18 heatmaps show expression of
significantly regulated proteins and are grouped according to 1) Highest protein expression by TNF/IL17 treatment at 20% O2. 2) Highest protein expression by
TNF/IL17 treatment at 2%O2. 3) Highest protein expression by TNF treatment at 20%O2, and 4) Highest protein expression by TNF or TNF/IL17 treatment, similar at 20
and 2% O2 (B) CCL20, CXCL1, CXCL2, CXCL5, CXCL8, CXCL10 and CXCL11 protein concentrations (pg.ml
−1) in conditioned medium from minimum six assays
measured by ELISA. Left panels: paired data at 2 or 20% O2 across all treatments for the selected chemokines, analyzed with Wilcoxon matched-pairs signed rank test.
Significance level is indicated as p values or not significant (ns). Right panels: concentrations for each chemokine in 2% (blue) or 20% (red) O2 plotted as individual values
with mean and SD. Statistical analysis were performed on log2 transformed data (Supplementary Data Sheet 2). Alterations across different treatments within each
oxygen concentrations were analyzed with one-way ANOVA followed by Tukey’s multiple comparisons or Kruskal-Wallis test followed by Dunn’s multiple comparisons
test. Alterations across different oxygen concentrations within same treatment were analyzed by two-way ANOVA followed by Holm-Šídák multiple comparisons test.
*p < 0.05; red and blue asterisks show comparisons across different treatments within 20 and 2% O2 conditions, respectively. Black asterisks indicate significant
comparisons between 2 and 20% oxygen concentrations within a specific treatment.
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FIGURE 4 | Donor differences in global gene expression. The panels show unsupervized analysis (PCA) of RNA-Seq data of colonoids from six donors grown
continuously at 20% or at 2% O2 for the last 40h (A) PCA of the complete dataset, PC1 vs PC2 captures the influence of donor variations and oxygen level. The different
donors and oxygen concentrations are indicated by color coded symbols. Three treatment conditions per donor in each oxygen concentration (n  6) are shown (B) PCA
of data from each donor. Plot of PC2 vs. PC3 captures the effect of treatments in donors HC1-2 andUC2-3, while PC2 vs. PC4 and PC1 vs PC2 captures this effect
best for HC3 and UC1, respectively.
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enough to reduce oxidative damage but high enough for efficient
oxidative metabolism for different cell types. (Ferguson et al.,
2018; Timpano et al., 2019). Finding an optimal oxygen
concentration that mirrors the in vivo physiological range in
colon (<1%–3%), might require some optimization depending on
the type of experiments, organoid density and differentiation
protocol used. Growing organoids in smaller droplets or
reseeding to 2D monolayer could eliminate some variability in
local O2 environment across a culture well.
Organoid models that mimic human physiology have
potential to both reduce the reliance on animal models for
drug-testing and improve development of personalized
medicine in humans. To our knowledge this is the first study
that examines the effects of the IBD drug-targets TNF/IL17 on
colonoids at a more physiologically relevant oxygen
concentration. Our findings in the colonoids strongly indicate
that an oxygen concentration closer to the in vivo epithelial cell
environment is of essence in IBD-related experimental
pharmacology. Although our focus in the present work is in
the context of IBD, intestinal organoids can be used for drug-
testing and experimental pharmacology related to several other
diseases, including cancer. Future studies should focus on fine-
tuning the optimal oxygen conditions for long term as well as
short term studies, and determine possible cellular differences in
oxygen demands to enhance the translational value of the model
and gain insight into intestinal pathobiology.
FIGURE 5 | Donor differences in gene expression of IL23, IL1A and IL1B (A) PCA of colonoid gene expression in global gene expression data from ulcerative colitis
(UC, green) and healthy controls (HC, purple). Plot of PC2 vs PC3 captures the group effect (B) Expression of the IBD-relevant cytokines IL23A, IL1A and IL1B in
colonoids from HC (circles) and UC (squares), in 20% (red) or 2% (blue) O2 and treatment with TNF, TNF/IL17 or untreated control. Individual values (normalized reads)
with median are shown.
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